RU2330653C2 - Эйкозапентаеновая кислота (эпк) для лечения нервно-психической анорексии (на) и булимии - Google Patents
Эйкозапентаеновая кислота (эпк) для лечения нервно-психической анорексии (на) и булимии Download PDFInfo
- Publication number
- RU2330653C2 RU2330653C2 RU2005107416/14A RU2005107416A RU2330653C2 RU 2330653 C2 RU2330653 C2 RU 2330653C2 RU 2005107416/14 A RU2005107416/14 A RU 2005107416/14A RU 2005107416 A RU2005107416 A RU 2005107416A RU 2330653 C2 RU2330653 C2 RU 2330653C2
- Authority
- RU
- Russia
- Prior art keywords
- epa
- acid
- treatment
- day
- bulimia
- Prior art date
Links
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title claims abstract description 67
- 229960005135 eicosapentaenoic acid Drugs 0.000 title claims abstract description 67
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title claims abstract description 67
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 238000011282 treatment Methods 0.000 title claims abstract description 50
- 208000022531 anorexia Diseases 0.000 title abstract description 8
- 206010061428 decreased appetite Diseases 0.000 title abstract description 8
- 208000032841 Bulimia Diseases 0.000 claims abstract description 12
- 206010006550 Bulimia nervosa Diseases 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 17
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 16
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 12
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 11
- 235000020778 linoleic acid Nutrition 0.000 claims description 11
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 11
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 9
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 8
- 229960004232 linoleic acid Drugs 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 235000021342 arachidonic acid Nutrition 0.000 claims description 6
- 229940114079 arachidonic acid Drugs 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- 125000004494 ethyl ester group Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 26
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 26
- 229960002600 icosapent ethyl Drugs 0.000 description 21
- 235000013305 food Nutrition 0.000 description 11
- 230000006872 improvement Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000037213 diet Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000009231 family therapy Methods 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000004630 mental health Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 208000030814 Eating disease Diseases 0.000 description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 235000014632 disordered eating Nutrition 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000036651 mood Effects 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 206010012374 Depressed mood Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 230000006996 mental state Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001671 psychotherapy Methods 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 238000009223 counseling Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000020805 dietary restrictions Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 208000037824 growth disorder Diseases 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 3
- 230000036435 stunted growth Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 208000012866 low blood pressure Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000020802 micronutrient deficiency Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 230000036301 sexual development Effects 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000035943 Aphagia Diseases 0.000 description 1
- 101150031621 CGAS gene Proteins 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 206010016280 Fear of weight gain Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000594592 Lanugo Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000020979 dietary recommendations Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 230000010346 psychosocial stress Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0221480.7 | 2002-09-16 | ||
| GBGB0221480.7A GB0221480D0 (en) | 2002-09-16 | 2002-09-16 | Treatment of anorexia nervosa (AN) and bulimia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005107416A RU2005107416A (ru) | 2006-01-20 |
| RU2330653C2 true RU2330653C2 (ru) | 2008-08-10 |
Family
ID=9944164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005107416/14A RU2330653C2 (ru) | 2002-09-16 | 2003-09-16 | Эйкозапентаеновая кислота (эпк) для лечения нервно-психической анорексии (на) и булимии |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060135608A1 (enExample) |
| EP (1) | EP1556028A1 (enExample) |
| JP (1) | JP2006503031A (enExample) |
| KR (1) | KR20050042823A (enExample) |
| CN (1) | CN1694694A (enExample) |
| AU (1) | AU2003269138A1 (enExample) |
| BR (1) | BR0317857A (enExample) |
| CA (1) | CA2499142A1 (enExample) |
| GB (1) | GB0221480D0 (enExample) |
| HR (1) | HRP20050245A2 (enExample) |
| IS (1) | IS7744A (enExample) |
| MX (1) | MXPA05002943A (enExample) |
| NO (1) | NO20051847L (enExample) |
| NZ (1) | NZ538793A (enExample) |
| PL (1) | PL375726A1 (enExample) |
| RS (1) | RS20050226A (enExample) |
| RU (1) | RU2330653C2 (enExample) |
| TW (1) | TW200410682A (enExample) |
| WO (1) | WO2004024136A1 (enExample) |
| ZA (1) | ZA200502161B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2545988C1 (ru) * | 2013-11-12 | 2015-04-10 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы | Способ лечения хронического запора и функциональной анорексии |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| WO2005046668A1 (ja) * | 2003-11-14 | 2005-05-26 | Mochida Pharmaceutical Co., Ltd. | 言語障害予防・治療剤 |
| JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および／又はうつ症状の改善作用を有する組成物 |
| KR101578498B1 (ko) | 2006-12-28 | 2015-12-18 | 산토리 홀딩스 가부시키가이샤 | 신경 재생제 |
| CA2672513C (en) | 2007-02-15 | 2010-05-25 | Centre De Recherche Sur Les Biotechnologies Marines | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| US8816110B2 (en) | 2007-02-15 | 2014-08-26 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| WO2008113177A1 (en) | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| BRPI1011883A2 (pt) * | 2009-06-15 | 2016-09-13 | Amarin Pharma Inc | uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina |
| AU2012214260A1 (en) * | 2011-02-11 | 2013-07-25 | E. I. Du Pont De Nemours And Company | An eicosapentaenoic acid concentrate |
| US9447020B2 (en) | 2013-10-31 | 2016-09-20 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| WO2019153073A1 (en) | 2018-02-07 | 2019-08-15 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
| US20210130897A1 (en) * | 2018-04-16 | 2021-05-06 | Quadrant Biosciences Inc. | Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status |
| US11166933B2 (en) | 2018-05-03 | 2021-11-09 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
| CN109276262B (zh) * | 2018-07-30 | 2021-01-26 | 中国科学院心理研究所 | 一种用于筛选高危进食障碍的检测系统 |
| US12226390B2 (en) | 2019-07-21 | 2025-02-18 | Scf Pharma Inc. | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| US12144786B2 (en) | 2020-03-27 | 2024-11-19 | Homeostasis Therapeutics LLC | Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2123844C1 (ru) * | 1992-11-26 | 1998-12-27 | Скотиа Холдингс ПЛС | Способ лечения шизофрении |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
-
2002
- 2002-09-16 GB GBGB0221480.7A patent/GB0221480D0/en not_active Ceased
-
2003
- 2003-09-16 NZ NZ538793A patent/NZ538793A/en unknown
- 2003-09-16 RU RU2005107416/14A patent/RU2330653C2/ru not_active IP Right Cessation
- 2003-09-16 TW TW092125483A patent/TW200410682A/zh unknown
- 2003-09-16 PL PL03375726A patent/PL375726A1/xx not_active Application Discontinuation
- 2003-09-16 EP EP03750919A patent/EP1556028A1/en not_active Ceased
- 2003-09-16 KR KR1020057004483A patent/KR20050042823A/ko not_active Withdrawn
- 2003-09-16 CN CNA038251698A patent/CN1694694A/zh active Pending
- 2003-09-16 JP JP2004535695A patent/JP2006503031A/ja active Pending
- 2003-09-16 RS YUP-2005/0226A patent/RS20050226A/sr unknown
- 2003-09-16 US US10/528,114 patent/US20060135608A1/en not_active Abandoned
- 2003-09-16 AU AU2003269138A patent/AU2003269138A1/en not_active Abandoned
- 2003-09-16 HR HR20050245A patent/HRP20050245A2/hr not_active Application Discontinuation
- 2003-09-16 CA CA002499142A patent/CA2499142A1/en not_active Abandoned
- 2003-09-16 MX MXPA05002943A patent/MXPA05002943A/es not_active Application Discontinuation
- 2003-09-16 WO PCT/GB2003/003985 patent/WO2004024136A1/en not_active Ceased
- 2003-09-16 BR BR0317857-9A patent/BR0317857A/pt not_active IP Right Cessation
-
2005
- 2005-03-15 ZA ZA200502161A patent/ZA200502161B/en unknown
- 2005-03-15 IS IS7744A patent/IS7744A/is unknown
- 2005-04-15 NO NO20051847A patent/NO20051847L/no not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2123844C1 (ru) * | 1992-11-26 | 1998-12-27 | Скотиа Холдингс ПЛС | Способ лечения шизофрении |
Non-Patent Citations (3)
| Title |
|---|
| abstract. КРЫЛОВ Ю.Ф., Перспективы использования эйкозапентаеновой и докозагексаеновой кислот как лекарственных средств. Хим.-фармац. журн. 1991, т.25, №9, с.4-10. * |
| KATE LOVETT. Bulimia and Depression. May 2001 (2001-05-02), p.1-5, [он-лайн] [Найдено 2007.06.27] найдено из Интернет http://www.vanderbilt.edu/AnS/psychology/health_psychology/bulimia_depressio n.htm. * |
| формула. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2545988C1 (ru) * | 2013-11-12 | 2015-04-10 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы | Способ лечения хронического запора и функциональной анорексии |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ538793A (en) | 2007-05-31 |
| NO20051847L (no) | 2005-04-15 |
| ZA200502161B (en) | 2005-09-15 |
| US20060135608A1 (en) | 2006-06-22 |
| CN1694694A (zh) | 2005-11-09 |
| PL375726A1 (en) | 2005-12-12 |
| WO2004024136A1 (en) | 2004-03-25 |
| KR20050042823A (ko) | 2005-05-10 |
| EP1556028A1 (en) | 2005-07-27 |
| CA2499142A1 (en) | 2004-03-25 |
| BR0317857A (pt) | 2005-12-06 |
| JP2006503031A (ja) | 2006-01-26 |
| RS20050226A (sr) | 2007-09-21 |
| MXPA05002943A (es) | 2005-06-03 |
| AU2003269138A1 (en) | 2004-04-30 |
| GB0221480D0 (en) | 2002-10-23 |
| HRP20050245A2 (en) | 2005-10-31 |
| IS7744A (is) | 2005-03-15 |
| TW200410682A (en) | 2004-07-01 |
| RU2005107416A (ru) | 2006-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060135608A1 (en) | Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia | |
| US11957725B2 (en) | Methods for treating neurological disorders using nutrient compositions | |
| WO1995017889A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
| US20210353671A1 (en) | Compositions comprising cinnamaldehyde and zinc and methods of using such compositions | |
| HEFFRON et al. | Thyrotoxicosis presenting as choreoathetosis | |
| US20090012039A1 (en) | Use of methylcobalamin nasal spray to treat disorders | |
| US20260053764A1 (en) | Composition for preventing deterioration in cognitive function and/or improving cognitive function | |
| JP7294147B2 (ja) | 侵害受容性疼痛の予防又は改善用組成物 | |
| CN105050428A (zh) | 用于患21三体综合征、孤独症谱系障碍和/或多动或无多动的注意力缺陷障碍的人的食物补充剂 | |
| WO2022210856A1 (ja) | 睡眠の質を改善するための組成物 | |
| Roberts | The syndrome of narcolepsy and diabetogenic hyperinsulinism in the american negro: Its relationship to the pathogenesis of diabetes mellitus, obesity, dysrhythmias, and accelerated cardiovascular disease | |
| JP2016525132A (ja) | ｐ−アニスアルデヒドを使用する組成物及び方法 | |
| Walker et al. | Anti-epileptic medications | |
| CN117045652B (zh) | 犬尿喹啉酸在制备缓解和/或治疗神经性贪食症的药物中的应用 | |
| US20200261485A1 (en) | Compositions comprising 3'-o-glucuronide epicatechin and methods of making and using such compositions | |
| RU2154474C2 (ru) | Способ лечения алиментарной дистрофии | |
| Dighikar et al. | A Rare Case of Wilson’s Disease in a 17 Years Old Girl | |
| RU2637628C1 (ru) | Способ коррекции психосоматических проявлений у пациентов с синдромом раздраженной кишки | |
| CN114306346A (zh) | 拉莫三嗪在治疗系统性红斑狼疮中的应用 | |
| Cadwalader | IDIOPATHIC EPILEPSY COMPLICATED BY MOTOR APHASIA AND DIPLEGIA, WITH NECROPSY. | |
| Baro et al. | Oral Communications included in Education and Clinical Practice Symposia (1st Halfofthe Congress)(please refer to programme for timings) | |
| Hoffman | Emotional wellness: A supporting role for dietary supplements. | |
| CA | HYPOTENSYL | |
| Liggan et al. | Taking care of our folks: a manual for family members caring for the black elderly |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20080917 |